Mercer Global Advisors’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$723K Buy
72,133
+23,998
+50% +$222K ﹤0.01% 2083
2026
Q2
$403K Buy
48,135
+36,496
+314% +$333K ﹤0.01% 2498
2026
Q1
$105K Buy
+11,639
New +$184K ﹤0.01% 3005
2024
Q1
– Sell
-15,500
Closed -$70K – 1950
2023
Q4
$70K Sell
15,500
-200
-1% -$740 ﹤0.01% 1936
2023
Q3
$56K Buy
15,700
+700
+5% +$2.69K ﹤0.01% 1890
2023
Q2
$55K Hold
15,000
– – ﹤0.01% 1866
2023
Q1
$50K Hold
15,000
– – ﹤0.01% 1868
2022
Q4
$58K Hold
15,000
– – ﹤0.01% 1854
2022
Q3
$36K Hold
15,000
– – ﹤0.01% 1784
2022
Q2
$30K Buy
+15,000
New +$29.5K ﹤0.01% 1786

Other funds holding ADMA

Mercer Global Advisors's ADMA Position: Q3 2026 in Review

Mercer Global Advisors increased its ADMA Biologics (ADMA) stake by 50% in Q3 2026, buying an estimated $222K and bringing the position to 72,133 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Mercer Global Advisors first reported a position in ADMA in Q2 2022 and has held it in 10 quarters since. 330 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Mercer Global Advisors held 72,133 shares of ADMA Biologics worth $723K as of Q3 2026.
  • Mercer Global Advisors bought 23,998 ADMA Biologics shares in Q3 2026, an estimated $222K.
  • ADMA Biologics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #2083 holding.
  • Mercer Global Advisors first reported a position in ADMA Biologics in Q2 2022 and has held it in 10 quarters since.
  • 330 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.